Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 10/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14005412 | 1.00 | VDR (0.43) | VDR | |
| SCHEMBL14007195 | 0.97 | VDR (0.42) | VDR | |
| SCHEMBL14005411 | 0.90 | VDR (0.43) | VDR | |
| SCHEMBL4902101 | 0.90 | VDR (0.43) | VDR | |
| SCHEMBL14005352 | 0.90 | VDR (0.43) | VDR | |
| SCHEMBL14007192 | 0.88 | VDR (0.42) | VDR | |
| SCHEMBL4905838 | 0.88 | VDR (0.42) | VDR | |
| SCHEMBL26324070 | 0.85 | VDR (0.62) | VDR | |
| SCHEMBL26326203 | 0.82 | VDR (0.54) | VDR | |
| SCHEMBL26326175 | 0.82 | VDR (0.54) | VDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293647-A1 | Combined Use Of Vitamin D Derivatives And Anti-Proliferative Agents For Treating Bladder Cancer | BIOXELL S.P.A. (IT) | 2008-11-27 | — | — | US | disclosed |
| US-20080280859-A1 | GEMINI VITAMIN D3 COMPOUNDS AND METHODS OF USE THEREOF | BIOXELL S.P.A. (IT) | 2008-11-13 | — | — | US | disclosed |
| US-20080039434-A1 | Treatment of Interstitial Cystitis with Vitamin D Compounds | BIOXELL S. P.A. (IT) | 2008-02-14 | — | — | US | disclosed |
| US-20070054887-A1 | Methods for treating bladder dysfunction | BIOXELL S.P.A (IT) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280859-A1 | GEMINI VITAMIN D3 COMPOUNDS AND METHODS OF USE THEREOF | VDR, GC, CYP24A1 | VDR 1/4885 |
| US-20080293647-A1 | Combined Use Of Vitamin D Derivatives And Anti-Proliferative Agents For Treating Bladder Cancer | VDR, CYP24A1, CYP27B1 | VDR 1/4885 |
| US-20080039434-A1 | Treatment of Interstitial Cystitis with Vitamin D Compounds | VDR, CYP24A1, CYP2R1 | VDR 1/4885 |
| US-20070054887-A1 | Methods for treating bladder dysfunction | CYP27B1, CYP24A1, VDR | VDR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.